
Neurology
For the neurologist managing MS and migraine therapies — coverage, criteria, and appeals across all 51 states.
Every state, quantified for neurology
| State | Approved · CY25 | Rules | PA-required | Appeal | Criteria docs |
|---|---|---|---|---|---|
| ● Recent · CY2025 disclosures — click a state to drill in | |||||
| WAWashington▸ viewing | 88.2% | 23 | 100% | ✓ | 6 |
| COColorado | 91.8% | 21 | 95% | ✓ | 10 |
| OHOhio | 77.7% | 23 | 100% | ✓ | 14 |
| All states · A–Z | |||||
| AKAlaska | — | 13 | 100% | ✓ | 2 |
| ALAlabama | — | 21 | 100% | ✓ | 6 |
| ARArkansas | — | 23 | 100% | ✓ | 2 |
| AZArizona | — | 21 | 100% | ✓ | 6 |
| CACalifornia | — | 23 | 96% | ✓ | 7 |
| CTConnecticut | — | 21 | 100% | ✓ | 3 |
| DCDistrict of Columbia | — | 21 | 95% | ✓ | 9 |
| DEDelaware | — | 20 | 100% | ✓ | 3 |
| FLFlorida | — | 21 | 100% | ✓ | — |
| GAGeorgia | — | 23 | 96% | ✓ | 12 |
| HIHawaii | — | 21 | 95% | ✓ | 5 |
| IAIowa | — | 21 | 100% | ✓ | 6 |
| IDIdaho | — | 15 | 100% | ✓ | 1 |
| ILIllinois | — | 20 | 100% | ✓ | — |
| INIndiana | — | 21 | 100% | ✓ | 2 |
| KSKansas | — | 20 | 100% | ✓ | 11 |
| KYKentucky | — | 23 | 100% | ✓ | 3 |
| LALouisiana | — | 19 | 100% | ✓ | 9 |
| MAMassachusetts | — | 17 | 100% | ✓ | 1 |
| MDMaryland | — | 19 | 95% | ✓ | 9 |
| MEMaine | — | 19 | 100% | ✓ | 3 |
| MIMichigan | — | 19 | 100% | ✓ | 6 |
| MNMinnesota | — | 15 | 100% | ✓ | 2 |
| MOMissouri | — | 25 | 100% | ✓ | 1 |
| MSMississippi | — | 23 | 100% | ✓ | 8 |
| MTMontana | — | 15 | 100% | ✓ | 2 |
| NCNorth Carolina | — | 23 | 100% | ✓ | 6 |
| NDNorth Dakota | — | 15 | 100% | ✓ | — |
| NENebraska | — | 19 | 100% | ✓ | 3 |
| NHNew Hampshire | — | 19 | 100% | ✓ | — |
| NJNew Jersey | — | 19 | 100% | ✓ | 3 |
| NMNew Mexico | — | 15 | 100% | ✓ | 3 |
| NVNevada | — | 19 | 100% | ✓ | 16 |
| NYNew York | — | 21 | 100% | ✓ | 3 |
| OKOklahoma | — | 23 | 100% | ✓ | — |
| OROregon | — | 22 | 95% | ✓ | 3 |
| PAPennsylvania | — | 19 | 100% | ✓ | 8 |
| RIRhode Island | — | 15 | 100% | ✓ | — |
| SCSouth Carolina | — | 21 | 100% | ✓ | 7 |
| SDSouth Dakota | — | 13 | 100% | ✓ | — |
| TNTennessee | — | 21 | 100% | ✓ | 4 |
| TXTexas | — | 23 | 100% | ✓ | 39 |
| UTUtah | — | 21 | 100% | ✓ | 11 |
| VAVirginia | — | 23 | 96% | ✓ | 5 |
| VTVermont | — | 13 | 100% | ✓ | 6 |
| WIWisconsin | — | 21 | 100% | ✓ | 3 |
| WVWest Virginia | — | 16 | 100% | ✓ | 1 |
| WYWyoming | — | 15 | 100% | ✓ | 5 |
Washington — neurology, every program
Click any state in the table above to drill into its rules, approval rates, and appeal path.
● Rules verified as-of Jun 8, 2026- MS disease-modifying therapiesPA required
WA Medicaid PDL: non-preferred agents in this class require PA.
- CGRP inhibitors · migrainePA required
WA Medicaid PDL: non-preferred agents in this class require PA.
- CGRP inhibitors · migraine(UnitedHealthcare)PA required
UnitedHealthcare commercial (Advantage 3-Tier). Antimigraine-migraines; CGRP agents (AIMOVIG, NURTEC, QULIPTA, UBRELVY, ZAVZPRET) carry PA+ST+QL; triptans QL only [e.g. AIMOVIG, EMGALITY, NURTEC, QULIPTA]
- MS disease-modifying therapies(UnitedHealthcare)PA required
UnitedHealthcare commercial (Advantage 3-Tier). CNS-multiple sclerosis; all agents carry PA+QL+SP (MAVENCLAD adds ST) [e.g. AVONEX, KESIMPTA, MAVENCLAD, MAYZENT]
- CGRP inhibitors · migraine(Cigna)PA required
Cigna commercial (Advantage 3-Tier). CGRP mAbs and gepants carry PA [e.g. AIMOVIG, AJOVY, EMGALITY, NURTEC ODT]
- MS disease-modifying therapies(Cigna)PA required
Cigna commercial (Advantage 3-Tier). MS DMTs SP, injectables/orals PA (generics SP only) [e.g. AVONEX, KESIMPTA, MAYZENT, VUMERITY]
- CGRP inhibitors · migraine(Aetna (CVS Caremark))PA required
Aetna (CVS Caremark) commercial formulary. CGRP monoclonal antibodies, specialty PA/ST [e.g. AIMOVIG, EMGALITY, AJOVY (CGRP mAbs)]
- CGRP inhibitors · migraine(Anthem Blue Cross (Elevance))PA required
Anthem Blue Cross (Elevance) commercial formulary. CGRP receptor antagonist monoclonal antibodies: PA + QL [e.g. EMGALITY galcanezumab, CGRP monoclonal antibodies]
- MS disease-modifying therapies(Anthem Blue Cross (Elevance))PA required
Anthem Blue Cross (Elevance) commercial formulary. MS agents (interferons, NRF2, pyrimidine synthesis, K-channel blockers, oral): PA + SP; monoclonal abs vary [e.g. teriflunomide, dimethyl fumarate, interferon beta, TYSABRI natalizumab]
- CGRP inhibitors · migraine(Centene)PA required
Centene Part D (CMS formulary file, plan-grounded).
- MS disease-modifying therapies(Centene)PA required
Centene Part D (CMS formulary file, plan-grounded).
- CGRP inhibitors · migraine(Unitedhealthcare)PA required
Unitedhealthcare Part D (CMS formulary file, plan-grounded).
- MS disease-modifying therapies(Unitedhealthcare)PA required
Unitedhealthcare Part D (CMS formulary file, plan-grounded).
- CGRP inhibitors · migraine(Humana)PA required
Humana Part D (CMS formulary file, plan-grounded).
- MS disease-modifying therapies(Humana)PA required
Humana Part D (CMS formulary file, plan-grounded).
- MS disease-modifying therapies(Cigna)PA required
Cigna Part D (CMS formulary file, plan-grounded).
- CGRP inhibitors · migraine(Cigna)PA required
Cigna Part D (CMS formulary file, plan-grounded).
- CGRP inhibitors · migraine(Aetna)PA required
Aetna Part D (CMS formulary file, plan-grounded).
- MS disease-modifying therapies(Aetna)PA required
Aetna Part D (CMS formulary file, plan-grounded).
- CGRP inhibitors · migraine(Kaiser)PA required
Kaiser Part D (CMS formulary file, plan-grounded).
- MS disease-modifying therapies(Kaiser)PA required
Kaiser Part D (CMS formulary file, plan-grounded).
- MS disease-modifying therapies(Molina Healthcare)PA required
Molina Healthcare commercial formulary. MS agents, interferons, and pyrimidine-synthesis inhibitor all PA
- CGRP inhibitors · migraine(Molina Healthcare)PA required
Molina Healthcare commercial formulary. Ubrelvy/Ajovy/Emgality (gepants + CGRP mAbs) carry PA
Full criteria, sources & appeal paths — all 51 states.
You’ve seen the breadth and one state in full. The complete Neurologypack — every state’s criteria, source citations, and step-by-step appeal instructions — is one email away.
Assembled from Auth57’s rules + criteria corpus + 51-state appeal layer. Draft data — verify against the payer’s current policy before relying.